Filgotinib类风湿关节炎与溃疡性结肠炎临床开发项目中的主要不良心血管、血栓栓塞及恶性肿瘤事件
该整合分析汇总了filgotinib 100 mg或200 mg每日一次治疗类风湿关节炎(RA)和溃疡性结肠炎(UC)的所有II期和III期试验数据,暴露量分别超过12500患者年和2800患者年。总体人群中关注的不良事件(MACE、VTE、恶性肿瘤)发生率低,但≥65岁患者中MACE(RA患者)、恶性肿瘤(排除非黑色素瘤皮肤癌)及非黑色素瘤皮肤癌(RA或UC患者)的发生率呈数值升高。结论认为总体安全性数据与既往分析一致,≥65岁患者不良事件发生率数值升高,需进一步数据评估心血管危险因素的影响,未观察到一致的filgotinib剂量效应。
要点
- 总体人群中MACE、VTE和恶性肿瘤发生率低,与既往总体安全性分析一致。
- ≥65岁RA患者中MACE(100 mg与200 mg发生率相同)、恶性肿瘤及非黑色素瘤皮肤癌发生率数值升高。
- ≥65岁RA患者接受200 mg时VTE暴露调整发生率(95%CI)为0.3(0.1, 0.8)/100患者年;≥65岁UC患者无VTE事件。
核心结论
- 数据与既往总体安全性分析一致,显示总体研究人群中关注的不良事件发生率低。
- ≥65岁患者中关注的不良事件发生率数值升高;需进一步数据评估心血管危险因素的影响。
- 总体而言,本分析中filgotinib对关注的不良事件无一致的剂量效应。
研究设计与样本
- 整合分析至今所有研究filgotinib 100 mg或200 mg每日一次治疗RA和UC的II期和III期试验数据。
- 分析代表filgotinib在RA中超过12500患者年、在UC中超过2800患者年的暴露量。
主要发现
- 整合分析人群中关注的不良事件发生率低。
- ≥65岁患者中发生率数值 modest 升高,包括RA患者的MACE、RA或UC患者的恶性肿瘤(排除非黑色素瘤皮肤癌)及非黑色素瘤皮肤癌。
- VTE罕见;≥65岁RA患者接受filgotinib 200 mg时VTE暴露调整发生率(95%CI)为0.3(0.1, 0.8)/100患者年;≥65岁UC患者无VTE事件。
- ≥65岁RA患者中,MACE发生率在filgotinib 100 mg与200 mg之间相同;恶性肿瘤和非黑色素瘤皮肤癌发生率200 mg数值高于100 mg。
局限性
- 需进一步数据评估心血管危险因素的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse cardiovascular events (MACE), venous thromboembolism (VTE) and malignancies. METHODS: Data were integrated from all phase II and III trials that have investigated filgotinib 100 mg or 200 mg once daily in RA and UC to date. RESULTS: Analyses represent >12 500 (RA) and >2800 (UC) patient-years of exposure (PYE) to filgotinib. Incidences of AEI in the integrated analysis population were low. Modest numerical increases in incidence rates occurred in patients aged ≥65 years, including MACE (patients with RA), and malignancies (excluding non-melanoma skin cancer (NMSC)) and NMSC (patients with RA or UC). VTE was rare; in patients with RA aged ≥65 years receiving filgotinib 200 mg, exposure-adjusted incidence rate (95% CI) for VTE was 0.3 (0.1, 0.8)/100 PYE; no VTE events occurred in patients with UC aged ≥65 years. In patients with RA aged ≥65 years, MACE incidence rates were identical between filgotinib 100 mg and 200 mg; rates of malignancies and NMSC were numerically higher with 200 mg compared with 100 mg. CONCLUSIONS: Data are consistent with previous overall safety analyses demonstrating low rates of AEI in the overall study population. Numerically increased rates of AEI occurred in patients aged ≥65 years; further data are needed to assess the effect of CV risk factors. Overall, in this analysis, there was no consistent filgotinib dose effect on AEI.
引用
- Mariette X, Borchmann S, Aspeslagh S, et al. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025. PMID: 40037922. doi:10.1136/rmdopen-2024-005033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。